TCL1 TRANSGENIC MICE
UCLA Technology Available For Licensing |
TCL1 is a protooncogene overexpressed in many mature B cell lymphomas. TCL1 is also expressed in precursor T cells and absent by the CD4+ CD8+ stage of thymocyte development. In B cells, TCL1 is first expressed in pro-B cells, and is completely absent in memory B cells and plasma cells.
UCLA researchers have developed a murine model in which a TCL1 transgene is overexpressed in both B and T cells. These transgenic mice develop Burkitt-like lymphoma and diffuse large B cell lymphoma at 4 months. This phenotype is accompanied by attendant Bcl-6 expression and mutated JH antibody gene segments. Interestingly, TCL1 is a more powerful initiator of B cell malignancies when compared to the low frequency of T cell malignancies with this model. This is mirrored in humans as >85% of human immune system malignancies are B cell derived.
- Mouse model for immune system malignancies in B, T and granulocytes cells.
- Mouse model for B-cell selection, development, maturation, antibody production and signaling responses through PI3-kinase pathways.
- Mouse model for designing therapeutics against B-cell malignancies and preventing autoantibody production in autoimmune diseases.
Reference: UCLA Case No. 2002-274
Related Papers (Selected)
- 2002 99(22):14392-14397. Dysregulated TCL1 Promotes Multiple Classes of Mature B Cell Lymphoma. more...
For additional technical details and current licensing
please contact the following UCLA office:
UCLA Office of Intellectual Property
11000 Kinross Avenue, Suite #200
Los Angeles, CA 90095-7231
Tel: 310-794-0558 Fax: 310-794-0638
NCD URL: http://www.research.ucla.edu/tech/ucla02-274.htm
UCLA Technologies Available for
Copyright © 2006 The Regents of the
University of California.
keywords: research tools, mouse model
uclancd ucla technologies intellectual property patents technology transfer invention business card